STAT1 Gain-of-Function and Hidradenitis Suppurativa Successfully Managed with Baricitinib

被引:0
作者
Peter Olbrich
José Ivorra Cortés
Olaf Neth
Pilar Blanco-Lobo
机构
[1] Red de Investigación Translacional en Infectología Pediátrica RITIP,Paediatric Infectious Diseases, Rheumatology and Immunology Unit, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, IBiS/Universidad de Sevilla/CSIC
[2] Universidad de Sevilla,Departamento de Farmacología, Pediatría y Radiología. Facultad de Medicina
[3] Hospital Universitari I Politècnic La Fe,Servicio de Reumatología
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:898 / 901
页数:3
相关论文
共 28 条
  • [1] Deya-Martinez A(2022)Impact of JAK inhibitors in pediatric patients with STAT1 gain of function (GOF) mutations-10 children and review of the literature J Clin Immunol 42 1071-1082
  • [2] Riviere JG(2020)Hidradenitis suppurativa Nat Rev Dis Primers 6 18-1361
  • [3] Roxo-Junior P(2014)The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers J Clin Pharmacol 54 1354-973
  • [4] Ramakers J(2020)Transcriptomic analysis of hidradenitis suppurativa skin suggests roles for multiple inflammatory pathways in disease pathogenesis Inflamm Res 69 967-1506
  • [5] Bloomfield M(2021)SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance? J Clin Immunol 41 1502-undefined
  • [6] Guisado Hernandez P(undefined)undefined undefined undefined undefined-undefined
  • [7] Sabat R(undefined)undefined undefined undefined undefined-undefined
  • [8] Jemec GBE(undefined)undefined undefined undefined undefined-undefined
  • [9] Matusiak L(undefined)undefined undefined undefined undefined-undefined
  • [10] Kimball AB(undefined)undefined undefined undefined undefined-undefined